search
Back to results

Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism

Primary Purpose

Tobacco Use Disorder

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
extinction training (nicotine cues)
extinction training (neutral cues)
Time-restricted smoking cessation
Time-restricted fasting
Time-restricted fasting with food supplemnet
Sponsored by
Shenzhen Kangning Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use Disorder focused on measuring nicotine, orexin, craving, withdrawal

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Nicotine addicts who meet the DSM-V diagnostic criteria for substance dependence, that is, smoking ≥ 10 cigarettes per day and smoking age ≥ 2 years; Communicate normally with the researcher and cooperate with the researchers; Exclusion Criteria: Psychotic symptoms or a family history of mental disorders; A history of dependence or behavior (gambling, online games) addiction other than alcohol, drugs, etc.; Use benzodiazepines or received antipsychotic drugs within 2 weeks; Epilepsy, craniocerebral injury history, coma history, brain organic or serious physical disease; Body mass index (BMI) > 30 ; Can not tolerate magnetic resonance examinations.

Sites / Locations

  • Shenzhen Kangning Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Sham Comparator

No Intervention

Arm Label

smoking cessation combining with nicotine cue extinction training

smoking cessation combining with neutral cue extinction training

smoking cessation combining with fasting and nicotine cue extinction training

smoking cessation combining with fasting and neutral cue extinction training

smoking cessation combining with early lifting of fast and nicotine cue extinction training

healthy control

Arm Description

Participants should stop smoking after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Participants should stop smoking after 18:00 the night before the test, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.

Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts are repeatedly presented with nicotine cue picture stimuli for extinction training, which lasts for 25 minutes.

Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.

Participants should stop smoking and eating food after 18:00 the night before the test. After breakfast at 8:00 in the morning, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.

Non-smoker healthy subjects matched with the smoking group in terms of age, gender, education level, etc. were used as the control group. Those healthy participants will finish fMRI scanning task.

Outcomes

Primary Outcome Measures

Change from baseline in smoking craving on Visual Analog Scale of Cigarette Craving at week 2
Nicotine-specific Visual Analog Scale is a valid measurements of craving for a cigarette. Possible scores range from 0 (no craving) to 10 (want cigarette imediately). Change= (Week 2 score - baseline score)
change from baseline in smoking craving on Visual Analog Scale of Cigarette Craving at week 4
Nicotine-specific Visual Analog Scale is a valid measurements of craving for a cigarette. Possible scores range from 0 (no craving) to 10 (want cigarette imediately). Change= (Week 2 score - baseline score)
Change from baseline in orexin level at 24 hours after administration of extinction training.
Collect 5ml of venous blood from particicpants and use a detection kit to detect orexin level.

Secondary Outcome Measures

Fagerstrom Nicotine Dependence Test
The Fagerström Test for Nicotine Dependence is a standard instrument for assessing the intensity of physical addiction to nicotine. The test was designed to provide an ordinal measure of nicotine dependence related to cigarette smoking. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence.

Full Information

First Posted
June 14, 2023
Last Updated
October 12, 2023
Sponsor
Shenzhen Kangning Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05947162
Brief Title
Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism
Official Title
Effect of Orexin System on Nicotine Addiction Among Smokers and Its Neural Mechanism
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 1, 2023 (Anticipated)
Primary Completion Date
July 31, 2027 (Anticipated)
Study Completion Date
July 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shenzhen Kangning Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to reveal the role and mechanism of orexin in nicotine addicts, compared to healthy control. The main questions it aims to answer are: Whether nicotine addiction-related behaviors, including nicotine withdrawal symptoms, cue-induced increased psychological craving, and relapse behavior are related to plasma orexin levels ? What is the neural mechanism of the orexin system in the fMRI brain network? Participants will be asked to do as followed: Day 1: Fill in the scale, test the concentration of exhaled CO, collect 5ml of blood from the vein, and take about 60 minutes. Day 1-3: Test and record the amount of smoking for 3 days, about 5 minutes. Day 4-5: Collect fMRI data, for about 60 minutes, perform extinction training, for about 30 minutes Day 6: Fill in the scale, test the concentration of CO in exhaled breath, collect 5ml of venous blood, test after subsidence and ignition test, and collect fMRI data, for about 60 minutes. Follow-up (2 weeks/4 weeks): Complete the follow-up on smoking craving and relapse by phone within 2 weeks, about 5 minutes, and complete the scale and collect fMRI data in the 4th week, about 60 minutes.
Detailed Description
Background: Smoking has always been a serious public health problem in my country. Nicotine is the main addictive ingredient in tobacco, the mechanism of nicotine addiction is not yet clear, and there is a lack of effective means to intervene in nicotine addiction. In recent years, the role of the orexin system in nicotine addiction has attracted great attention. Multiple preclinical studies have consistently found that orexin receptor antagonists have a significant intervention effect on nicotine addiction. Objective: This study focuses on the role and mechanism of orexin in nicotine addiction, and will reveal the neurobiological basis of orexin in nicotine addicts after withdrawal, and its potential as a biomarker for predicting and preventing relapse possible. Methods: This study will combine neuropsychology, neuroimaging, and detection of plasma orexin expression levels to explore whether nicotine addiction-related behaviors, including nicotine withdrawal symptoms, cue-induced increased psychological craving, and relapse behavior are related to plasma orexin Levels are associated, and further explore the neural mechanism of its brain network. Based on the detection of plasma orexin, it is of great theoretical and clinical significance to verify whether it is used as a peripheral blood biomarker of nicotine addiction and to establish an objective evaluation index of nicotine addiction. More specifically, participants need to finish following aims: Scale evaluation: Minnesota Tobacco Withdrawal Symptom Scale, Smoking Craving Scale, Short Smoking Craving Questionnaire, Nicotine Dependence Level Test to evaluate nicotine dependence and Smoking Intensity Index Scale, and record the subjects' smoking index (smoking Years × number of cigarettes smoked per day/20), and the smoking craving visual analog scale was used to indicate the degree of smoking craving. In addition, the Montreal Cognitive Scale, Barratt Impulsivity Scale, Self-Rating Anxiety Scale, Self-Rating Depression Scale, Hamilton Anxiety and Depression Scale and Pittsburgh Sleep Scale were collected for about 60 minutes. Behavioral extinction training: On the 4th and 5th days, combined with cue exposure therapy, nicotine addicts were repeatedly presented with nicotine cue/neutral cue picture stimulation for extinction training, which lasted for 25 minutes. Collect fMRI data: including resting state fMRI and task state fMRI on the 4th and 6th day, about 60 minutes. Detection of blood orexin level: 5ml of venous blood was collected on the 1st, 4th, and 6th day, and the plasma orexin-A level was measured by enzyme-linked immunosorbent assay. Time and method of follow-up: Follow up the subjects through outpatient clinics, telephone, WeChat, etc., record the relapse situation within 2 weeks after the intervention, record the number of cigarettes smoked every day, and return after 1 month for nicotine withdrawal Symptoms and smoking cravings were assessed, and DTI, resting state fMRI and task state fMRI data were collected for about 60 minutes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use Disorder
Keywords
nicotine, orexin, craving, withdrawal

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
smoking cessation combining with nicotine cue extinction training
Arm Type
Experimental
Arm Description
Participants should stop smoking after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
Arm Title
smoking cessation combining with neutral cue extinction training
Arm Type
Placebo Comparator
Arm Description
Participants should stop smoking after 18:00 the night before the test, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.
Arm Title
smoking cessation combining with fasting and nicotine cue extinction training
Arm Type
Experimental
Arm Description
Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts are repeatedly presented with nicotine cue picture stimuli for extinction training, which lasts for 25 minutes.
Arm Title
smoking cessation combining with fasting and neutral cue extinction training
Arm Type
Placebo Comparator
Arm Description
Participants should stop smoking and eating food after 18:00 the night before the test. Combined with cue exposure therapy, nicotine addicts were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
Arm Title
smoking cessation combining with early lifting of fast and nicotine cue extinction training
Arm Type
Sham Comparator
Arm Description
Participants should stop smoking and eating food after 18:00 the night before the test. After breakfast at 8:00 in the morning, they are combined with cue exposure therapy, by repeatedly presenting neutral cue picture stimuli to nicotine addicts, and performing extinction training for 25 minutes.
Arm Title
healthy control
Arm Type
No Intervention
Arm Description
Non-smoker healthy subjects matched with the smoking group in terms of age, gender, education level, etc. were used as the control group. Those healthy participants will finish fMRI scanning task.
Intervention Type
Behavioral
Intervention Name(s)
extinction training (nicotine cues)
Intervention Description
extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
Intervention Type
Behavioral
Intervention Name(s)
extinction training (neutral cues)
Intervention Description
extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
Intervention Type
Behavioral
Intervention Name(s)
Time-restricted smoking cessation
Intervention Description
Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
Intervention Type
Behavioral
Intervention Name(s)
Time-restricted fasting
Other Intervention Name(s)
Dietary intervention
Intervention Description
Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
Intervention Type
Behavioral
Intervention Name(s)
Time-restricted fasting with food supplemnet
Other Intervention Name(s)
Dietary intervention
Intervention Description
Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
Primary Outcome Measure Information:
Title
Change from baseline in smoking craving on Visual Analog Scale of Cigarette Craving at week 2
Description
Nicotine-specific Visual Analog Scale is a valid measurements of craving for a cigarette. Possible scores range from 0 (no craving) to 10 (want cigarette imediately). Change= (Week 2 score - baseline score)
Time Frame
baseline and week 2
Title
change from baseline in smoking craving on Visual Analog Scale of Cigarette Craving at week 4
Description
Nicotine-specific Visual Analog Scale is a valid measurements of craving for a cigarette. Possible scores range from 0 (no craving) to 10 (want cigarette imediately). Change= (Week 2 score - baseline score)
Time Frame
baseline and week 4
Title
Change from baseline in orexin level at 24 hours after administration of extinction training.
Description
Collect 5ml of venous blood from particicpants and use a detection kit to detect orexin level.
Time Frame
baseline and 24 hours after administration of extinction training.
Secondary Outcome Measure Information:
Title
Fagerstrom Nicotine Dependence Test
Description
The Fagerström Test for Nicotine Dependence is a standard instrument for assessing the intensity of physical addiction to nicotine. The test was designed to provide an ordinal measure of nicotine dependence related to cigarette smoking. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence.
Time Frame
baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Nicotine addicts who meet the DSM-V diagnostic criteria for substance dependence, that is, smoking ≥ 10 cigarettes per day and smoking age ≥ 2 years; Communicate normally with the researcher and cooperate with the researchers; Exclusion Criteria: Psychotic symptoms or a family history of mental disorders; A history of dependence or behavior (gambling, online games) addiction other than alcohol, drugs, etc.; Use benzodiazepines or received antipsychotic drugs within 2 weeks; Epilepsy, craniocerebral injury history, coma history, brain organic or serious physical disease; Body mass index (BMI) > 30 ; Can not tolerate magnetic resonance examinations.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Gengdi Huang, PhD
Phone
+86 18600251858
Email
gengdihuang@pku.edu.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Qi Wang, PhD
Phone
+86 13688819667
Email
16981017@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gengdi Huang, PhD
Organizational Affiliation
Shenzhen Kangning Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shenzhen Kangning Hospital
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518118
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qi Wang, Phd
Phone
+86 13688819667
Email
16981017@qq.com
First Name & Middle Initial & Last Name & Degree
Gengdi Huang, Phd

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism

We'll reach out to this number within 24 hrs